Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie

Abstract : The development of personalized medicine in oncology is based on biomarkers that help select populations for more efficient and less toxic therapies. The onset of molecular biology led to new paradigms in drug development, with efficacy data reported in early clinical trials and accelerated approvals. Multiple clinical trials, including SHIVA, SAFIR-01 and MOSCATO-01, have been developed to evaluate the interest of treatment decision-making based on tumor molecular profiling, with the ambition to replace historical clinical and pathological classifications. Targeted molecular therapies have also drastically enhanced the prognosis of patients in several cancer subtypes, with increased use in the context of advanced palliative care. Breaking through those boundaries might lead to a true precision medicine in oncology, which implementation in clinical routine is now expected by patients and physicians.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02370054
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : mardi 19 novembre 2019 - 11:57:08
Dernière modification le : vendredi 6 décembre 2019 - 15:18:41

Identifiants

Citation

Ronan Flippot, Christophe Massard, Édouard Auclin, David Azria, Heloise Bourien, et al.. Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie. Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (9), pp.735-743. ⟨10.1016/j.bulcan.2017.07.003⟩. ⟨hal-02370054⟩

Partager

Métriques

Consultations de la notice

37